Study of Niraparib Combined with Bevacizumab Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Why is the OVARIO study being done?

This clinical trial will look at how safe and effective niraparib is when given together with bevacizumab in women with Stage IIIB to IV ovarian cancer who have a complete response or partial response following front-line, platinum-based chemotherapy with bevacizumab. 

NOTE: Enrollment goal has been reached.
This study is no longer enrolling new participants.

  • Before enrollment, at least 3 cycles of bevacizumab together with the last 3 cycles of platinum-based chemotherapy. Women who have interval debulking surgery are eligible if they have received only 2 cycles of bevacizumab together with the last 3 cycles of platinum-based chemotherapy.

  • High-grade serous or endometrioid or high-grade predominantly serous or endometrioid histology, regardless of HRD or gBRCA mutation status. Women with non-mucinous epithelial ovarian cancer and a gBRCA mutation are eligible.

  • Must have had 1 attempt at optimal debulking surgery.

  • History of bowel obstruction related to the underlying disease or history of abdominal fistula, GI perforation, or intra-abdominal abscesses.

  • Other than ovarian cancer, diagnosed or treated for invasive cancer less than 5 years before study enrollment. Women with cervical carcinoma in situ, non-melanomatous skin cancer, and ductal carcinoma in situ definitively treated are allowed.

  • Women with clinically significant cardiovascular disease. (The Study Doctor will explain “clinically significant.”)


The best next step is to contact the research site that would be the most convenient for you in order to discuss your medical history and whether the OVARIO clinical trial would be a good fit.

To find sites in your area, contact: or use the form above.

To find additional information on OVARIO see: